AMGEN and Repatha at ACC

Flexible dosing from the comfort of home1

1 injection. No titration.
Every 2 weeks
Repatha® SureClick®

    Single-dose prefilled autoinjector

  • 140 mg/dL subcutaneous injection
  • Hidden 27-gauge needle
  • Delivers the 140 mg/dL dose subcutaneously in up to 15 seconds
Once a month
Repatha® Pushtronex® System

    Single-dose on-body infusor with prefilled cartridge

  • 420 mg/3.5 mL subcutaneous injection
  • Hidden 29-gauge needle
  • Steady delivery of the 420 mg/3.5 mL dose subcutaneously in up to 5 minutes
of patients successfully administer at home with either device2,*,†

References: 1. Repatha® (evolocumab) prescribing information, Amgen. 2. Dent R, Joshi R, Djedjos CS, et al. Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting. SpringerPlus. 2016;5:300.

  • Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.
  • Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Please click red ^ to view additional Important Safety Information.

Please see full Prescribing Information.